Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) EBIT (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed EBIT for 7 consecutive years, with $349.4 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 449.32% to $349.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$16.8 million through Dec 2025, up 95.96% year-over-year, with the annual reading at -$16.8 million for FY2025, 95.96% up from the prior year.
  • EBIT for Q4 2025 was $349.4 million at Beam Therapeutics, up from -$126.8 million in the prior quarter.
  • The five-year high for EBIT was $349.4 million in Q4 2025, with the low at -$200.4 million in Q1 2021.
  • Average EBIT over 5 years is -$67.0 million, with a median of -$99.5 million recorded in 2023.
  • The sharpest move saw EBIT plummeted 606.66% in 2021, then surged 449.32% in 2025.
  • Over 5 years, EBIT stood at -$63.5 million in 2021, then crashed by 40.17% to -$89.0 million in 2022, then soared by 249.3% to $132.9 million in 2023, then plummeted by 175.3% to -$100.0 million in 2024, then soared by 449.32% to $349.4 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at $349.4 million, -$126.8 million, and -$120.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.